IL103928A0 - Expression of specific immunogens using viral antigens - Google Patents

Expression of specific immunogens using viral antigens

Info

Publication number
IL103928A0
IL103928A0 IL103928A IL10392892A IL103928A0 IL 103928 A0 IL103928 A0 IL 103928A0 IL 103928 A IL103928 A IL 103928A IL 10392892 A IL10392892 A IL 10392892A IL 103928 A0 IL103928 A0 IL 103928A0
Authority
IL
Israel
Prior art keywords
expression
viral antigens
specific immunogens
immunogens
specific
Prior art date
Application number
IL103928A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL103928A0 publication Critical patent/IL103928A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL103928A 1991-12-11 1992-11-30 Expression of specific immunogens using viral antigens IL103928A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80510591A 1991-12-11 1991-12-11

Publications (1)

Publication Number Publication Date
IL103928A0 true IL103928A0 (en) 1993-04-04

Family

ID=25190685

Family Applications (1)

Application Number Title Priority Date Filing Date
IL103928A IL103928A0 (en) 1991-12-11 1992-11-30 Expression of specific immunogens using viral antigens

Country Status (17)

Country Link
US (1) US5591823A (fi)
EP (1) EP0546787A3 (fi)
JP (1) JPH05262667A (fi)
KR (1) KR930013112A (fi)
CN (1) CN1073878A (fi)
AU (1) AU2981992A (fi)
BR (1) BR9204978A (fi)
CA (1) CA2084180A1 (fi)
CZ (1) CZ362692A3 (fi)
FI (1) FI925590A (fi)
HU (2) HUT65366A (fi)
IL (1) IL103928A0 (fi)
MX (1) MX9207113A (fi)
NO (1) NO924780L (fi)
SK (1) SK362692A3 (fi)
TW (1) TW239162B (fi)
ZA (1) ZA929355B (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
WO1995007099A1 (fr) * 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccin et procede pour sa production
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
DE69535716T2 (de) * 1995-05-26 2009-03-19 Protein Sciences Corp., Meriden Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
AU7471098A (en) * 1997-04-30 1998-11-24 Mount Sinai School Of Medicine Of The City University Of New York, The Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
EP1318923B1 (en) 2000-09-11 2006-01-11 Dow Global Technologies Inc. A run flat tire support and colorant therefor
JP2007524609A (ja) * 2003-04-10 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド コンフォメーションに関する変種のプロファイリング、抗体組成物
EP1906998A4 (en) * 2005-06-01 2010-02-17 Variation Biotechnologies Inc GRAPE VACCINE FORMULATION ON PEPTIDE BASE
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RU2532105C2 (ru) 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
CN101708442B (zh) * 2009-09-04 2011-08-24 山东中惠仪器有限公司 全自动标准气体配制装置
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
MX2018009395A (es) * 2016-02-03 2018-11-09 Cg Discovery Inc Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
EP0492920A1 (en) * 1990-12-24 1992-07-01 Merck & Co. Inc. Chimaeric influenza-HIV vaccine

Also Published As

Publication number Publication date
FI925590A0 (fi) 1992-12-09
FI925590A (fi) 1993-06-12
AU2981992A (en) 1993-06-17
SK362692A3 (en) 1995-11-08
KR930013112A (ko) 1993-07-21
CA2084180A1 (en) 1993-06-12
HU9203931D0 (en) 1993-04-28
JPH05262667A (ja) 1993-10-12
CZ362692A3 (en) 1994-02-16
NO924780L (no) 1993-06-14
US5591823A (en) 1997-01-07
HUT65366A (en) 1994-05-02
MX9207113A (es) 1994-05-31
CN1073878A (zh) 1993-07-07
BR9204978A (pt) 1993-06-15
TW239162B (fi) 1995-01-21
EP0546787A2 (en) 1993-06-16
NO924780D0 (no) 1992-12-10
ZA929355B (en) 1994-06-02
HU211548A9 (en) 1995-12-28
EP0546787A3 (en) 1994-06-01

Similar Documents

Publication Publication Date Title
EP0546787A3 (en) Expression of specific immunogens using viral antigens
PL324906A1 (en) Vaccines against viral hepatitis of c type
GB8822749D0 (en) Vaccine containing tumour antigens & adjuvants
PL321966A1 (en) Vaccine against viral hepatitis of b type
AU4325089A (en) Viral vaccines
GB8907914D0 (en) Vaccine preparation
EP0391997A4 (en) Vaccine
HUP9601466A2 (en) Adjuvants for viral vaccines
HUP9601462A2 (en) Adjuvants for viral vaccines
LTIP335A (en) Vaccine for human immunodeficiency virus
IL79740A0 (en) Hepatitis vaccine
GB8704647D0 (en) Vaccine
GB9020683D0 (en) Isolation of dna
ZA896372B (en) Vaccine
ZA94740B (en) Expression of pretective antigens
GB9020799D0 (en) Viral vaccines
GB9104903D0 (en) Viral vaccines
GB8712042D0 (en) Virus & vaccine
GB8622883D0 (en) Expression of hepatitis b viral antigens
GB9117602D0 (en) Novel antigens
GB9122301D0 (en) Novel antigens
HU907120D0 (en) In-vitro mass microproliferation of lilies by means of histogenesis
GB8621578D0 (en) Hepatitis b viral antigens
GB8821078D0 (en) Improvements relating to antigens
ZA891686B (en) Improvements relating to antigens